The central function of the Advanced Technologies core (ATC) will be to support GNL researchers in? translating basic science knowledge and discoveries into practical measures to improve human health.? Research undertaken in the GNL will identify many new potential targets for therapeutics and diagnostics? against life threatening infectious diseases. In fulfilling its central function the first service that the ATC will? provide will be the resources and expertise to develop in vitro assays that utilize such new targets and? technologies, from the research bench top to a standardized, reproducible and validated format suitable that? can be used in medium to high throughput screening (HTS) studies. Wherever possible the ATC will place? emphasis on developing assays that can be conducted under low containment BSL2 conditions which will? maximize their subsequent utility to the research community. However, not all assays developed will be? suitable for BSL2 use and, effective validation of many of the BSL2 assays will require confirmatory studies? using live pathogens under BSL3 or BSL4 containment. Therefore, as part of its in vitro assay development? function the core will not only maintain BSL2 containment resources but will have the resources to conduct? assay development under BSL3 and BSL4 containment conditions.? The second service that the ATC will provide to the GNL will be infrastructure to conduct HTS studies using? the assays that it develops, or other already existing assays under both BSL2 and BSL3 containment with? the additional capacity to conduct small scale studies under BSL4 containment. This screening program will? provide GNL researchers with the ability to identify active compounds to serve as leads for development of? potential new therapeutics.? The third major service of the ATC will be to coordinate interactions between GNL researchers and those? resources and expertise in specialized research cores that already exist on the UTMB campus. In this role? the ATC will contribute directly to the cost effective running of the GNL in two distinct ways. Firstly, it will? ensure that GNL researchers make full use of existing resources rather than duplicating them and,? secondly, it will minimize the time and effort involved in individual researchers accessing these resources on? an ad hoc basis by acting as a single source point of access. This will directly increase research efficiency? for the GNL.?

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
National Biocontainment Laboratory Operation Cooperative Agreement (UC7)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Medical Br Galveston
United States
Zip Code
Andersson, Jourdan A; Sha, Jian; Kirtley, Michelle L et al. (2018) Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics. Antimicrob Agents Chemother 62:
Beasley, David W C; Brasel, Trevor L; Comer, Jason E (2016) First vaccine approval under the FDA Animal Rule. NPJ Vaccines 1:16013
Sha, Jian; Kirtley, Michelle L; Klages, Curtis et al. (2016) A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates. Clin Vaccine Immunol 23:586-600
Fitts, Eric C; Andersson, Jourdan A; Kirtley, Michelle L et al. (2016) New Insights into Autoinducer-2 Signaling as a Virulence Regulator in a Mouse Model of Pneumonic Plague. mSphere 1:
Tiner, Bethany L; Sha, Jian; Cong, Yingzi et al. (2016) Immunisation of two rodent species with new live-attenuated mutants of Yersinia pestis CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague. NPJ Vaccines 1:16020
Andersson, Jourdan A; Fitts, Eric C; Kirtley, Michelle L et al. (2016) New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria. Antimicrob Agents Chemother 60:3717-29
Tiner, Bethany L; Sha, Jian; Kirtley, Michelle L et al. (2015) Combinational deletion of three membrane protein-encoding genes highly attenuates yersinia pestis while retaining immunogenicity in a mouse model of pneumonic plague. Infect Immun 83:1318-38
Rasmussen, Lynn; Tigabu, Bersabeh; White, E Lucile et al. (2015) Adapting high-throughput screening methods and assays for biocontainment laboratories. Assay Drug Dev Technol 13:44-54
Boisen, Matthew L; Schieffelin, John S; Goba, Augustine et al. (2015) Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. Viral Immunol 28:19-31
Falzaran, D; Bente, D A (2015) Animal models for viral haemorrhagic fever. Clin Microbiol Infect :

Showing the most recent 10 out of 43 publications